JP7113415B1 - 変異型mad7タンパク質 - Google Patents
変異型mad7タンパク質 Download PDFInfo
- Publication number
- JP7113415B1 JP7113415B1 JP2022011914A JP2022011914A JP7113415B1 JP 7113415 B1 JP7113415 B1 JP 7113415B1 JP 2022011914 A JP2022011914 A JP 2022011914A JP 2022011914 A JP2022011914 A JP 2022011914A JP 7113415 B1 JP7113415 B1 JP 7113415B1
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- mutant
- mad7
- acid sequence
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000952182 Homo sapiens Max-like protein X Proteins 0.000 title claims abstract description 105
- 102100037423 Max-like protein X Human genes 0.000 title claims abstract description 105
- 230000035772 mutation Effects 0.000 claims abstract description 89
- 238000006467 substitution reaction Methods 0.000 claims abstract description 49
- 230000000694 effects Effects 0.000 claims abstract description 22
- 235000001014 amino acid Nutrition 0.000 claims description 118
- 150000001413 amino acids Chemical group 0.000 claims description 99
- 229940024606 amino acid Drugs 0.000 claims description 82
- 108091033319 polynucleotide Proteins 0.000 claims description 38
- 102000040430 polynucleotide Human genes 0.000 claims description 38
- 239000002157 polynucleotide Substances 0.000 claims description 38
- 238000010362 genome editing Methods 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 21
- -1 aromatic amino acid Chemical class 0.000 claims description 16
- 239000004475 Arginine Substances 0.000 claims description 13
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 11
- 239000004472 Lysine Substances 0.000 claims description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 10
- 108091026890 Coding region Proteins 0.000 claims description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 9
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 9
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 8
- 235000009582 asparagine Nutrition 0.000 claims description 8
- 229960001230 asparagine Drugs 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 88
- 238000003776 cleavage reaction Methods 0.000 abstract description 22
- 230000007017 scission Effects 0.000 abstract description 22
- 210000004027 cell Anatomy 0.000 description 49
- 238000012360 testing method Methods 0.000 description 40
- 238000003556 assay Methods 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 19
- 239000013604 expression vector Substances 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 125000000539 amino acid group Chemical group 0.000 description 9
- 235000002374 tyrosine Nutrition 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108010054624 red fluorescent protein Proteins 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000004474 valine Substances 0.000 description 6
- 229960004295 valine Drugs 0.000 description 6
- 235000014393 valine Nutrition 0.000 description 6
- 229940123611 Genome editing Drugs 0.000 description 5
- 108020005004 Guide RNA Proteins 0.000 description 5
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 238000000099 in vitro assay Methods 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 5
- 235000014705 isoleucine Nutrition 0.000 description 5
- 229960003136 leucine Drugs 0.000 description 5
- 235000005772 leucine Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000004400 serine Nutrition 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 235000008521 threonine Nutrition 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 235000004554 glutamine Nutrition 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000010453 CRISPR/Cas method Methods 0.000 description 3
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 3
- 229960002064 kanamycin sulfate Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 2
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108700004991 Cas12a Proteins 0.000 description 1
- 241001481710 Cerambycidae Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000251556 Chordata Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000002488 Nucleoplasmin Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010076818 TEV protease Proteins 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 241000251555 Tunicata Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 241001531188 [Eubacterium] rectale Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000441 neoplastic stem cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108060005597 nucleoplasmin Proteins 0.000 description 1
- 210000000196 olfactory nerve Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
本明細書中において、「含有」及び「含む」なる表現については、「含有」、「含む」、「実質的にからなる」及び「のみからなる」という概念を含む。
本発明は、その一態様において、配列番号1に示されるアミノ酸配列Aが変異してなるアミノ酸配列Bを含み、且つ前記アミノ酸配列Bが、前記アミノ酸配列AにおけるK169及びD529のアミノ酸置換変異を含む、変異型MAD7タンパク質(本明細書において、「本発明の変異型MAD7タンパク質」と示すこともある。)に関する。以下に、これについて説明する。
1. アミノ酸配列B´からhomology modeling により立体構造を得る。
2. ドメインをまたぐ領域毎に1箇所を切断サイトとして選ぶ。この際、複数のモデル構造を比較し、構造上不都合のないと考えられる候補を優先的に選択する。
3. 結果的にsplit可能と考えられるサイトを選択する。
本発明は、その一態様において、本発明の変異型MAD7タンパク質のコード配列を含む、ポリヌクレオチド(本明細書において、「本発明のポリヌクレオチド」と示すこともある。)、本発明のポリヌクレオチド、及び本発明の変異型MAD7タンパク質からなる群より選択される少なくとも1種を含む、細胞(本明細書において、「本発明の細胞」と示すこともある。)に関する。以下に、これらについて説明する。
本発明は、その一態様において本発明の変異型MAD7タンパク質、及び本発明のポリヌクレオチドからなる群より選択される少なくとも1種を細胞又は非ヒト生物に導入することを含む、ゲノム編集方法、に関する。
本発明は、その一態様において、本発明の変異型MAD7タンパク質、本発明のポリヌクレオチド、及び本発明の細胞からなる群より選択される少なくとも1種を含む、ゲノム編集用組成物(本明細書において、「本発明のゲノム編集用組成物」と示すこともある。)、に関する。以下に、これについて説明する。
試験例1-1.MAD7発現ベクターの調製
MAD7タンパク質(配列番号1)のC末端にNLS(配列番号4)及び3×HAタグ(配列番号5)を付加してなるタンパク質(ST7:図1及び2)のコード配列、変異型MAD7タンパク質(配列番号2:配列番号1にK169R、D529R、K970N、及びY1086Fが導入されてなる配列)のC末端にNLS(配列番号4)及び3×HAタグ(配列番号5)を付加してなるタンパク質(ST8-1:図1及び3)のコード配列、変異型MAD7タンパク質(配列番号3:配列番号1にK169R、D529R、Y1086F、及びE1227Kが導入されてなる配列)のC末端にNLS(配列番号4)及び3×HAタグ(配列番号5)を付加してなるタンパク質(ST8-2:図1及び4)のコード配列を、発現ベクターのCMVプロモーターの下流に挿入し、MAD7発現ベクターを得た。
U6 promoterの下流にscaffold-crRNA-terminator配列が挿入されたベクターを調製した。
EF-1α promoterの下流に赤色蛍光タンパク質(RFP)が挿入されたベクターを調製した。
CAG promoterの下流にEGFP アミノ基末端領域、PAM配列を含む切断される塩基配列、EGFP カルボキシル基末端領域の順番で挿入されたベクターを調製した。当該ベクターは、ゲノム編集により切断されるとEGFP配列の修復が起こり、緑色蛍光が観察されるようにデザインされている。
各MAD7発現ベクター(試験例1)を用いて、変異型MAD7タンパク質の標的部位に対する切断活性を測定した。具体的には以下のようにして行った。
(1)HEK293T細胞を24 well plateに撒き、1.5日間から2日間、37℃でCO2インキュベーター内にて培養した。培地はDMEM (High Glucose)(Sigma-Aldrich), 10%FBS(CAPRICORN), 1xペニシリンーストレプトマイシン混合溶液(ナカライテクス)を使用した。
(2)以下の混合液を作製した。
A液:Opti-MEM(Gibco)600μl、 2ng/ 2nl RFP発現ベクター 0.6μl、 2 ng/ 2nl crRNA発現ベクター1.2μl、2ng/ 2nl EGxxFP assay検出用ベクター3μl
B液:Opti-MEM 600μl、 Turbofect(Thermo Fisher Scientific) 24μl
(3)A液を各チューブ75μlずつ分注し、0.4 ng/nl ST7またはST8発現ベクターを0.75μl混合した。
(4)(3)で作製した液にB液75μlを加え、よく混合させ、室温で20分静置した。
(5)24 well plateの培地を新しい培地に交換した。
(6)24well plateの各wellに(4)で作製した液50μlを加えて、軽くゆすった。
(7)1.5日から2日間培養した後、トリプシン処理により細胞を回収し、Passive Lysis 5x Buffer(Promega)の希釈液を加えて激しく撹拌し、細胞を破壊した。
(8)12000 rpm 5分で遠心し、上清を回収した。各サンプルの上清50μlを96 well plateの2 wellに加え、上清に含まれるEGFPとRFPの蛍光強度をプレートリーダー(CYTATION3 imaging reader (BioTek))で検出した。
(9)EGFPの値をRFPの値で標準化した。MAD7発現ベクターを含まないサンプルをネガティブコントロールとし、各サンプルの値から、ネガティブコントロールの値を引く。ST7の値を1とし、それ以外のサンプルの値はST7の相対値を示した。各データは個体数3で、誤差範囲は標準誤差で示した。結果を図5~25に示す。
大腸菌タンパク質発現系pETシステムを用いてMAD7ならびに、変異型MAD7タンパク質の精製を行った。具体的には以下のようにして行った。
(1)MAD7もしくは変異型MAD7のコード配列(試験例1)を含むpET発現ベクターをRosettaTM (DE3) Competent cells(Sigma-Aldrich)に形質転換し、カナマイシン硫酸塩を含んだLB寒天培地上で培養した。37℃で1日間インキュベートさせ、大腸菌コロニーの形成を確認した。
(2)形成したコロニーから1コロニー選出し、カナマイシン硫酸塩を含んだLB液体培地10mlで37℃ 180rpm 6時間培養した(preculture)。
(3)バッフル付三角フラスコ10個にそれぞれprecultureしたLB培養液 1mlと100mlのカナマイシン硫酸塩を含んだLB液体培地を入れ、37℃ 180rpm 8時間インキュベートした。
(4)氷上で15分静置した後、最終濃度0.5mMになるようにIPTG (Merk)を添加し、25℃ 130rpm 6時間インキュベートした。
(5)4℃ 3000g 10分で遠心し上清を除去、さらに大腸菌ペレットをPBSで洗浄した。
(6)大腸菌ペレットをリゾチーム処理ならびに超音波処理し、4℃ 70000xg 30分で遠心した後、可溶性画分を回収した。
(7)可溶性画分をNGCTM クロマトグラフィーシステム(Bio-Rad)を使用したカラムクロマトグラフィーで分離・精製を行った。
(8)分離・精製したMAD7ならびに変異型MAD7は、SDS-PAGEで電気泳動した後、CBB染色(Wako)で確認した。
(1)CBB染色により、MAD7タンパク質(試験例3)とST8.2タンパク質(試験例3)の量比を算出した。
(2)同濃度のMAD7タンパク質溶液10μlとST8.2タンパク質溶液10μl、NEBuffer 3.1 2μl、crRNA [配列: /AlTR1/rUrArArUrUrUrCrUrArCrUrCrUrUrGrUrArGrArUrUrGrUrCrArCrCrArArUrCrCrUrGrUrCrCrCrUrArG(配列番号6)/AlTR2/](100 ng/μl) 3μl、滅菌水を混合し、25℃で10分静置した。
(3)500ngになるように、基質DNAを加え、反応液量を20μlにした。
(4)37℃、30℃、25℃の条件で、1時間と24時間反応させた。
(5)4μl 10 x loading bufferを加えた。
(6)2%アガロースゲルで10μlの反応溶液を泳動した。
(7)ゲル撮影装置で撮影し、ImageJで切断されていない切断用DNA量を測定した。
(8)100x((コントロールの基質DNA量-切断されていない基質DNA基質)/コントロールの基質DNA量)の計算式で、切断活性を算出した。結果を図26~29に示す。
(1)マウス受精卵に同濃度のMAD7またはST8.2とマウスRosa26遺伝子座に設計したcrRNA[配列: /AlTR1/rUrArArUrUrUrCrUrArCrUrCrUrUrGrUrArGrArUrCrArCrCrUrGrUrUrCrArArUrUrCrCrCrCrUrGrCrA/AlTR2/](配列番号7)をGEEP法(特開2017-184639号公報)により挿入した。
(2)エレクトロポレーションを行った受精卵を37℃, CO2インキュベーターでE3.5-4.5まで培養し、桑実胚または胚盤胞に発生した受精卵を個別に回収した。
(3)回収した受精卵よりDNAを抽出した。
(4)Rosa26遺伝子座に設計したcrRNAの標的配列を検出するプライマーを用いてPCRを行った。
(5)Miseq reagent nano kit v2を用いてDNAシーケンス解析を行った。
(6)Rosa26遺伝子座において、ゲノムDNAの切断に起因する変異を確認した。
(7)100×(Rosa26遺伝子座においてゲノムDNAの切断に起因する変異が検出された検体数/全検体数)の計算式で、切断効率を算出した。結果を図30に示す。
Claims (19)
- 配列番号1に示されるアミノ酸配列Aが変異してなるアミノ酸配列Bを含み、前記アミノ酸配列Bが、前記アミノ酸配列AにおけるK169及びD529のアミノ酸置換変異を含み、K169の変異後のアミノ酸がアルギニンであり、D529の変異後のアミノ酸がアルギニンであり、且つ前記アミノ酸配列Bの前記アミノ酸配列Aに対するアミノ酸変異の数が50個以下である、標的部位に対する切断活性を有する変異型MAD7タンパク質。
- 前記アミノ酸配列Bが、前記アミノ酸配列AにおけるY1086のアミノ酸置換変異を含む、請求項1に記載の変異型MAD7タンパク質。
- 前記アミノ酸置換変異において、Y1086の変異後のアミノ酸がチロシン以外の芳香族アミノ酸である、請求項2に記載の変異型MAD7タンパク質。
- 前記アミノ酸置換変異において、Y1086の変異後のアミノ酸がフェニルアラニンである、請求項2又は3に記載の変異型MAD7タンパク質。
- 前記アミノ酸配列Bが、前記アミノ酸配列AにおけるK970及びE1227からなる群より選択される少なくとも1種のアミノ酸のアミノ酸置換変異を含む、請求項1~4のいずれかに記載の変異型MAD7タンパク質。
- 前記アミノ酸置換変異において、K970の変異後のアミノ酸が親水性中性アミノ酸であり、且つ/或いはE1227の変異後のアミノ酸が塩基性アミノ酸である、請求項5に記載の変異型MAD7タンパク質。
- 前記アミノ酸置換変異において、K970の変異後のアミノ酸がアスパラギンであり、且つ/或いはE1227の変異後のアミノ酸がリシンである、請求項5又は6に記載の変異型MAD7タンパク質。
- 前記アミノ酸配列Bが、前記アミノ酸配列AにおけるM961、K1098、F1198、Q1230、I1231、及びN1250からなる群より選択される少なくとも1種のアミノ酸のアミノ酸置換変異を含む、請求項1~7のいずれかに記載の変異型MAD7タンパク質。
- 前記アミノ酸配列Bが、前記アミノ酸配列AにおけるC892、Y907、I922、Y966、S1000、T1014、K1040、L1056、I1065、K1067、T1083、F1163、D1200、K1236、D1238、F1241、S1242、及びK1247からなる群より選択される少なくとも1種のアミノ酸のアミノ酸置換変異を含む、請求項1~8のいずれかに記載の変異型MAD7タンパク質。
- 前記アミノ酸配列B及び核局在化シグナル配列を含む、請求項1~9のいずれかに記載の変異型MAD7タンパク質。
- 請求項1~10のいずれかに記載の変異型MAD7タンパク質のコード配列を含む、ポリヌクレオチド。
- 請求項11に記載のポリヌクレオチド、及び請求項1~10のいずれかに記載の変異型MAD7タンパク質からなる群より選択される少なくとも1種を含む、細胞。
- 請求項1~10のいずれかに記載の変異型MAD7タンパク質、及び請求項11に記載のポリヌクレオチドからなる群より選択される少なくとも1種を細胞又は非ヒト生物に導入することを含む、ゲノム編集方法。
- 請求項1~10のいずれかに記載の変異型MAD7タンパク質、請求項11に記載のポリヌクレオチド、及び請求項12に記載の細胞からなる群より選択される少なくとも1種を含む、実験用ゲノム編集用組成物。
- 請求項1~10のいずれかに記載の変異型MAD7タンパク質、請求項11に記載のポリヌクレオチド、及び請求項12に記載の細胞からなる群より選択される少なくとも1種を含む、農業用ゲノム編集用組成物。
- 請求項1~10のいずれかに記載の変異型MAD7タンパク質、請求項11に記載のポリヌクレオチド、及び請求項12に記載の細胞からなる群より選択される少なくとも1種を含む、医療用ゲノム編集用組成物。
- 請求項1~10のいずれかに記載の変異型MAD7タンパク質、請求項11に記載のポリヌクレオチド、及び請求項12に記載の細胞からなる群より選択される少なくとも1種を含む、畜産用ゲノム編集用組成物。
- 請求項1~10のいずれかに記載の変異型MAD7タンパク質、請求項11に記載のポリヌクレオチド、及び請求項12に記載の細胞からなる群より選択される少なくとも1種を含む、水産用ゲノム編集用組成物。
- 請求項1~10のいずれかに記載の変異型MAD7タンパク質、請求項11に記載のポリヌクレオチド、及び請求項12に記載の細胞からなる群より選択される少なくとも1種を含む、工業用ゲノム編集用組成物。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022011914A JP7113415B1 (ja) | 2022-01-28 | 2022-01-28 | 変異型mad7タンパク質 |
ARP230100168A AR128340A1 (es) | 2022-01-28 | 2023-01-26 | Proteína mutante mad7, composiciones y usos |
EP23747043.0A EP4299747A1 (en) | 2022-01-28 | 2023-01-26 | Mutant mad7 protein |
PCT/JP2023/002475 WO2023145833A1 (ja) | 2022-01-28 | 2023-01-26 | 変異型mad7タンパク質 |
CN202380010972.6A CN117157404A (zh) | 2022-01-28 | 2023-01-26 | 突变型mad7蛋白 |
US18/553,112 US20240182879A1 (en) | 2022-01-28 | 2023-01-26 | Mutant mad7 protein |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022011914A JP7113415B1 (ja) | 2022-01-28 | 2022-01-28 | 変異型mad7タンパク質 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP7113415B1 true JP7113415B1 (ja) | 2022-08-05 |
JP2023110449A JP2023110449A (ja) | 2023-08-09 |
Family
ID=82740507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022011914A Active JP7113415B1 (ja) | 2022-01-28 | 2022-01-28 | 変異型mad7タンパク質 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20240182879A1 (ja) |
EP (1) | EP4299747A1 (ja) |
JP (1) | JP7113415B1 (ja) |
CN (1) | CN117157404A (ja) |
AR (1) | AR128340A1 (ja) |
WO (1) | WO2023145833A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023027041A1 (ja) | 2021-08-23 | 2023-03-02 | グランドグリーン株式会社 | 部位特異的ヌクレアーゼ |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020086475A1 (en) | 2018-10-22 | 2020-04-30 | Inscripta, Inc. | Engineered enzymes |
WO2021257716A2 (en) | 2020-06-16 | 2021-12-23 | Bio-Techne Corporation | Engineered mad7 directed endonuclease |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6980218B2 (ja) | 2016-04-01 | 2021-12-15 | 国立大学法人徳島大学 | Cas9タンパク質を哺乳動物の受精卵に導入する方法 |
JP2022100914A (ja) | 2020-12-24 | 2022-07-06 | アクア株式会社 | 冷蔵庫 |
-
2022
- 2022-01-28 JP JP2022011914A patent/JP7113415B1/ja active Active
-
2023
- 2023-01-26 AR ARP230100168A patent/AR128340A1/es unknown
- 2023-01-26 WO PCT/JP2023/002475 patent/WO2023145833A1/ja active Application Filing
- 2023-01-26 EP EP23747043.0A patent/EP4299747A1/en active Pending
- 2023-01-26 US US18/553,112 patent/US20240182879A1/en active Pending
- 2023-01-26 CN CN202380010972.6A patent/CN117157404A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020086475A1 (en) | 2018-10-22 | 2020-04-30 | Inscripta, Inc. | Engineered enzymes |
WO2021257716A2 (en) | 2020-06-16 | 2021-12-23 | Bio-Techne Corporation | Engineered mad7 directed endonuclease |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023027041A1 (ja) | 2021-08-23 | 2023-03-02 | グランドグリーン株式会社 | 部位特異的ヌクレアーゼ |
Also Published As
Publication number | Publication date |
---|---|
US20240182879A1 (en) | 2024-06-06 |
CN117157404A (zh) | 2023-12-01 |
EP4299747A1 (en) | 2024-01-03 |
JP2023110449A (ja) | 2023-08-09 |
AR128340A1 (es) | 2024-04-17 |
WO2023145833A1 (ja) | 2023-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102458395B1 (ko) | 프로그램가능한 dna 결합 단백질을 사용한, 표적화된 게놈 변형의 개선 | |
KR102655021B1 (ko) | 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용 | |
US10767193B2 (en) | Engineered CAS9 systems for eukaryotic genome modification | |
CN113711046B (zh) | 用于揭示与Tau聚集相关的基因脆弱性的CRISPR/Cas脱落筛选平台 | |
US11965184B2 (en) | CRISPR/Cas fusion proteins and systems | |
KR20200017479A (ko) | Crispr/cas 활성제 시스템용 합성 유도 rna | |
WO2023145833A1 (ja) | 変異型mad7タンパク質 | |
KR102683424B1 (ko) | 타우 응집과 관련된 유전적 취약성을 식별하기 위한 CRISPR/Cas 드랍아웃 스크리닝 플랫폼 | |
JP6956995B2 (ja) | ゲノム編集方法 | |
JP2020065506A (ja) | 核酸結合因子 | |
KR20130069188A (ko) | 마이오스타틴을 표적으로 하는 징크 핑거 뉴클레아제 및 이의 용도 | |
JP7356739B2 (ja) | 核酸結合性タンパク質 | |
RU2808829C2 (ru) | Платформа crispr/cas для исключающего скрининга для выявления генетических уязвимостей, связанных с агрегацией тау-белка | |
JP2019062841A (ja) | Cpf1タンパク質導入方法 | |
KR102684890B1 (ko) | 진핵 게놈 변형을 위한 조작된 cas9 시스템 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220128 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20220128 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220308 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220405 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220420 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220524 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220607 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220714 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7113415 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |